Today: 29 April 2026
Salesforce stock (CRM) slides as Anthropic AI plug-ins rattle software names before open
4 February 2026
1 min read

Salesforce stock (CRM) slides as Anthropic AI plug-ins rattle software names before open

NEW YORK, Feb 4, 2026, 07:05 (EST) — Premarket

Salesforce shares dropped 6.9% to close at $196.38 on Tuesday, drawing renewed attention to the cloud-software giant ahead of Wednesday’s U.S. trading session.

The focus has shifted from the price action to the underlying cause. Traders are zeroing in on a straightforward concern: “AI agents”—software designed to perform tasks for users—might undercut the value subscription software commands, threatening growth projections down the line.

AI developer Anthropic rolled out plug-ins for its Claude Cowork agent, enabling connections to tools that automate tasks in legal, sales, marketing, and data analysis. The announcement rattled U.S. and European software and data-analytics stocks, which tumbled sharply Tuesday. The S&P 500 slid 0.84%, while the Nasdaq dropped 1.43%. “Sometimes the market just shoots first and asks questions later,” said Mike Archibald, a portfolio manager at AGF Investments. Reuters

Salesforce’s core subscription model is under strain. The majority of clients continue to pay per user seat, a setup Wall Street values for its steady renewal revenue. But if AI tools lead to fewer seats being sold or more aggressive price negotiations, even a slight change could disrupt valuation calculations.

JPMorgan analyst Toby Ogg described investor appetite as “very low,” highlighting a focus on longer-term growth over the upcoming quarter. He added, “The sector isn’t just guilty until proven innocent but is now being sentenced before trial.” Meanwhile, Quilter Cheviot’s Ben Barringer noted that investors are largely steering clear of the software market altogether. Reuters

Broader markets showed more stability early Wednesday, yet the software sector remains battered. The S&P 500 software and services index has plunged over 12% in the last five sessions, marking its toughest run since March 2020, Reuters reported.

Salesforce isn’t the only one feeling the pressure. The selloff has targeted cloud and data stocks broadly, dragging down firms with vastly different balance sheets and short-term outlooks.

Salesforce director Amy Chang disclosed in a company filing that she was granted 1,766 restricted stock units on Feb. 1. These RSUs will vest in quarterly instalments through November, according to a Form 4 filing.

This story could still pivot on a single headline. If the AI disruption thesis seems exaggerated, or if investors reckon the selloff already factors in most of the bad news, software stocks might rebound fast. The flip side is true as well: more evidence that AI tools displace paid seats could prolong the de-rating.

Wednesday’s data on risk appetite and megacap earnings are next in focus. The ADP private-payrolls report arrives at 8:15 a.m. ET, followed by Alphabet’s earnings later in the day. Amazon is set to release its numbers on Thursday.

Stock Market Today

  • Nasdaq Futures Rise Ahead of Fed Decision and Major Tech Earnings
    April 29, 2026, 9:10 AM EDT. Nasdaq futures gained 0.4% ahead of the Federal Reserve's policy decision and earnings reports from tech giants Alphabet, Microsoft, Amazon, and Meta. Markets are cautious following a broad sell-off in major indices driven by chip stock weakness linked to slowing growth at AI firm OpenAI. Investors await the Fed's stance on inflation and interest rates, with crude oil prices rising amid unresolved US-Iran tensions. The Fed is expected to hold rates steady in Jerome Powell's final meeting before his replacement, Kevin Warsh, awaits Senate approval. Key focus remains on AI capital expenditure and the potential for further rate hikes in 2024. Earnings from AbbVie, AstraZeneca, Total Energies, UBS, and GSK are also in focus.

Latest article

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

29 April 2026
Humana beat first-quarter profit estimates, earning $10.31 per share adjusted, but shares fell over 6% premarket after it kept its 2026 profit outlook unchanged and cut its GAAP earnings forecast. Revenue rose to $39.65 billion. The insurer cited lower Medicare Star Ratings for the earnings decline and said medical and pharmacy costs are “slightly better” than expected. Competitors Centene, UnitedHealth, and Elevance recently raised their annual forecasts.
Crude oil prices today: Brent and WTI climb on U.S.-Iran tension as inventory report looms
Previous Story

Crude oil prices today: Brent and WTI climb on U.S.-Iran tension as inventory report looms

Nvidia Stock Slides in Early Trade as OpenAI Chip Doubts and AI Selloff Bite
Next Story

Nvidia Stock Slides in Early Trade as OpenAI Chip Doubts and AI Selloff Bite

Go toTop